SUBOXONE (BUPRENORPHINE/NALOXONE) AS AN AGONIST OPIOID TREATMENT IN SPAIN: A BUDGETARY IMPACT ANALYSIS
Saved in:
MARTINEZ-RAGA, J., ET AL., SUBOXONE (BUPRENORPHINE/NALOXONE) AS AN AGONIST OPIOID TREATMENT IN SPAIN: A BUDGETARY IMPACT ANALYSIS. EUROPEAN ADDICTION RESEARCH, Vol. 16, no. 1 (2010), p. 31-42.
Ref.
166449
Location:
SIIS R.1142
Palabras clave:
Buprenorfina, Coste, Drogas ilegales, Drogodependencias, Efectos, Evaluación de servicios, Fármacos, Metadona, Opiáceos, Programas de mantenimiento, Reducción de daños, Tratamiento médico, España
Buprenorfina, Coste, Drogas ilegales, Drogodependencias, Efectos, Evaluación de servicios, Fármacos, Metadona, Opiáceos, Programas de mantenimiento, Reducción de daños, Tratamiento médico, España
Similar Items: SUBOXONE (BUPRENORPHINE/NALOXONE) AS AN AGONIST OPIOID TREATMENT IN SPAIN: A BUDGETARY IMPACT ANALYSIS
- A PILOT STUDY OF BUPRENORPHINE-NALOXONE COMBINATION TABLET (SUBOXONE) IN TREATMENT OF OPIOID DEPENDENCE
- FROM MORPHINE CLINICS TO BUPRENORPHINE: REGULATING OPIOID AGONIST TREATMENT OF ADDICTION IN THE UNITED STATES
- The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers
- The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada
- SUBLINGUAL BUPRENORPHINE/NALOXONE PRECIPITATED WITHDRAWAL IN SUBJECTS MAINTAINED ON 100 MG OF DAILY METHADONE
- The LASSO Program in Oslo: Harm reduction using buprenorphine-naloxone (Suboxone®) in a low threshold setting